Traynor Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-323
Closed -$58K 229
2022
Q4
$58K Buy
+323
New +$52.8K 0.01% 198
2022
Q1
Sell
-5,869
Closed -$1.49M 225
2021
Q4
$1.49M Buy
5,869
+5,198
+775% +$1.52M 0.18% 72
2021
Q3
$258K Buy
+671
New +$247K 0.04% 159

Other funds holding MRNA

Traynor Capital Management's MRNA Position: Q1 2023 in Review

Traynor Capital Management sold out of Moderna (MRNA) in Q1 2023, closing a stake of 323 shares — an estimated $58K sold.

Traynor Capital Management first reported a position in MRNA in Q3 2021 and held it in 3 quarters. The position peaked at $1.49M in Q4 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Traynor Capital Management reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Traynor Capital Management sold 323 Moderna shares in Q1 2023, an estimated $58K.
  • Traynor Capital Management first reported a position in Moderna in Q3 2021 and held it in 3 quarters.
  • Traynor Capital Management's Moderna position peaked at $1.49M in Q4 2021.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Traynor Capital Management's 13F filing for Q1 2023, filed 21 Apr 2023.